📣 VC round data is live. Check it out!

CVRx Valuation Multiples

Discover revenue and EBITDA valuation multiples for CVRx and similar public comparables like Owlet, MEZOO, Viromed Medical, EBR Systems and more.

CVRx Overview

About CVRx

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.


Founded

2000

HQ

United States

Employees

223

Website

cvrx.com

Financials (LTM)

Revenue: $60M
EBITDA: ($43M)

EV

$147M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CVRx Financials

CVRx reported last 12-month revenue of $60M and negative EBITDA of ($43M).

In the same LTM period, CVRx generated $51M in gross profit, ($43M) in EBITDA losses, and had net loss of ($53M).

Revenue (LTM)


CVRx P&L

In the most recent fiscal year, CVRx reported revenue of $57M and EBITDA of ($44M).

CVRx is unprofitable as of last fiscal year, with gross margin of 85%, EBITDA margin of (77%), and net margin of (94%).

See analyst estimates for CVRx
LTMLast FY202320242025202620272028
Revenue$60M$57M$39M$51M$57M
Gross Profit$51M$48M$33M$43M$48M
Gross Margin86%85%84%84%85%
EBITDA($43M)($44M)($39M)($55M)($47M)
EBITDA Margin(72%)(77%)(99%)(107%)(83%)
EBIT Margin(84%)(90%)(110%)(116%)(90%)
Net Profit($53M)($53M)($41M)($60M)($53M)
Net Margin(89%)(94%)(105%)(117%)(94%)

Financial data powered by Morningstar, Inc.

CVRx Stock Performance

CVRx has current market cap of $160M, and enterprise value of $147M.

Market Cap Evolution


CVRx's stock price is $6.01.

CVRx share price decreased by 19.9% in the last 30 days, and by 9.3% in the last year.

CVRx has an EPS (earnings per share) of $-2.01.

See more trading valuation data for CVRx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$147M$160M1.5%-19.9%-26.3%-9.3%$-2.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CVRx Valuation Multiples

CVRx trades at 2.4x EV/Revenue multiple, and (3.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for CVRx

EV / Revenue (LTM)


CVRx Financial Valuation Multiples

As of May 20, 2026, CVRx has market cap of $160M and EV of $147M.

CVRx has a P/E ratio of (3.0x).

LTMLast FY202320242025202620272028
EV/Revenue2.4x2.6x3.7x2.9x2.6x
EV/EBITDA(3.4x)(3.3x)(3.8x)(2.7x)(3.1x)
EV/EBIT(2.9x)(2.9x)(3.4x)(2.5x)(2.9x)
EV/Gross Profit2.9x3.0x4.4x3.4x3.0x
P/E(3.0x)(3.0x)(3.9x)(2.7x)(3.0x)
EV/FCF(3.9x)(3.8x)(3.7x)(3.6x)(3.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CVRx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CVRx Margins & Growth Rates

CVRx grew revenue by 15% but EBITDA decreased by 5% in the last fiscal year.

In the most recent fiscal year, CVRx reported gross margin of 85%, EBITDA margin of (77%), and net margin of (94%).

See estimated margins and future growth rates for CVRx

CVRx Margins

Last FY202420252026202720282029
Gross Margin85%84%85%86%
EBITDA Margin(77%)(107%)(83%)(64%)
EBIT Margin(90%)(116%)(90%)(75%)
Net Margin(94%)(117%)(94%)(81%)
FCF Margin(68%)(79%)(72%)(56%)

CVRx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth15%31%10%15%
Gross Profit Growth16%30%13%16%
EBITDA Growth(5%)42%(15%)(11%)
EBIT Growth(4%)38%(14%)(4%)
Net Profit Growth(1%)46%(11%)(1%)
FCF Growth(5%)2%1%(10%)

Data powered by FactSet, Inc. and Morningstar, Inc.

CVRx Operational KPIs

CVRx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

CVRx's Rule of 40 is (48%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CVRx's Rule of X is (25%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for CVRx
LTMLast FY202320242025202620272028
Rule of 40(56%)(48%)
Bessemer Rule of X(32%)(25%)
Revenue per Employee$0.3M
Opex per Employee$0.4M
R&D Expenses to Revenue20%20%30%22%20%
Opex to Revenue176%194%200%176%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CVRx Competitors

CVRx competitors include Owlet, MEZOO, Viromed Medical, EBR Systems, Edap TMS, Apyx Medical, EKF Diagnostics, Sisram Medical, Aroa Biosurgery and Guerbet.

Most CVRx public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Owlet1.5x1.4x78.3x41.0x
MEZOO22.7x
Viromed Medical7.5x(657.4x)50.9x
EBR Systems119.4x26.8x(4.5x)(3.9x)
Edap TMS2.4x2.4x(8.0x)(7.7x)
Apyx Medical3.3x3.1x(45.4x)(44.2x)
EKF Diagnostics2.0x2.0x8.1x8.0x
Sisram Medical0.4x0.4x3.0x3.6x

This data is available for Pro users. Sign up to see all CVRx competitors and their valuation data.

Start Free Trial

CVRx Funding History

Before going public, CVRx raised $185M in total equity funding, across 4 rounds.


CVRx Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-20Undisclosed stageAction Potential Venture Capital; Gilde Healthcare; Hatteras Venture Partners; Johnson & Johnson Development Corporation; New Enterprise Associates; Treo Ventures; Venrock; Vensana Capital$50MCVRx, Inc. is a commercial-stage medical technology company focused on developing and commercializing neuromodulation solutions for heart failure and related cardiovascular conditions. Its lead product, Barostim Neo, is the world's first neuromodulation device for heart failure treatment, with FDA approval in the US and CE Mark in Europe for heart failure and drug-refractory hypertension. In July 2020, CVRx raised $50 million in a pre-IPO equity financing round led by Treo Ventures and Vensana Capital, with participation from Action Potential Venture Capital, Gilde Healthcare, Hatteras Venture Partners, Johnson & Johnson Development Corporation, New Enterprise Associates, and Venrock. The round supported CVRx's commercial activities ahead of its June 2021 IPO on Nasdaq under ticker CVRX, where it priced 7 million shares at $18 per share, raising approximately $126 million in gross proceeds. Treo Ventures General Partner Mudit K. Jain, PhD, joined the CVRx board following the financing. For the year ended December 31, 2020, CVRx reported revenue of $6.1 million with a gross margin of 76% and a net loss of $14.1 million. Revenue was negatively impacted by the COVID-19 pandemic, particularly restrictions on healthcare facilities starting in March 2020. The company had an accumulated deficit of $351.7 million as of that date. CVRx positioned itself as a first-mover in neuromodulation for large, underpenetrated cardiovascular markets, emphasizing long-term clinical data for safety, efficacy, adoption, and regulatory expansion.
Aug-19Series GAction Potential Venture Capital; Gilde Healthcare; Johnson & Johnson Development Corporation; New Enterprise Associates; Windham Venture Partners; Ysios Capital$93MCVRx, Inc. is a Minneapolis-based medical device company focused on neuromodulation treatments for heart failure and resistant hypertension. The company developed the Barostim Neo System, a neuromodulator device that activates baroreceptors in the carotid artery walls to modulate cardiac function and blood pressure through electrical impulses. In September 2019, CVRx secured $93 million in Series G equity financing from existing investors Johnson & Johnson Innovation, New Enterprise Associates, Inc., and Ysios BioFund I F.C.R, alongside new investors Gilde Healthcare Partners, Action Potential Venture Capital Limited, and Windham Venture Partners. The company also secured a separate $20 million term loan agreement with Oxford Finance LLC as part of the overall financing package. This Series G round represented the largest-ever funding round for CVRx at that time, bringing total capital raised to more than $283 million across five financing rounds since 2008. The proceeds were primarily designated to complete the Baroreflex Activation Therapy for Heart Failure Pivotal Clinical Trial (BeAT-HF), which tested the safety and efficacy of the Barostim Neo System. By 2021, CVRx reported annual revenue of $8.5 million, with a gross margin of 76% and a net loss of $14.1 million for that fiscal year. The company estimated its initial annual market opportunity for heart failure with reduced ejection fraction (HFrEF) at $1.4 billion in the United States and $1.5 billion across select European markets.
Oct-13Series FDaVita; Ysios Capital$12MCVRx, Inc. is a Minneapolis-based medical device company founded in 2001 that develops the Barostim neo, an implantable system designed to treat hypertension and heart failure by stimulating blood-pressure receptors in carotid arteries. The device received CE marking for hypertension treatment in Europe in 2012 and was under clinical evaluation in the United States and Europe for both hypertension and heart failure treatment. On October 30, 2013, CVRx closed on an additional $12 million under its Series F financing round, bringing the total raised in Series F to $42 million. New investors in this round included Spanish venture capital firm Ysios Capital and Denver-based DaVita HealthCare Partners Inc., a Fortune 500 company, with Josep Sanfeliu from Ysios Capital joining the company's Board of Directors. The company planned to deploy the capital primarily for advancing clinical trials and expanding international commercial activities. By 2013, CVRx had treated more than 625 patients with its patented devices and had raised approximately $41.7 million in venture capital during that year alone as part of its broader capital trajectory.
Jul-13Series FJohnson & Johnson Development Corporation; New Enterprise Associates; SightLine Partners; Sterling Capital Management$30MCVRx, Inc., a Minneapolis-based private medical device company founded in 2001, completed a $29.6 million private equity financing on July 10, 2013, co-led by New Enterprise Associates (NEA) and Johnson & Johnson Development Corporation, with participation from existing investors BBT Fund L.P. and SightLine Partners. The company develops the Barostim neo, an implantable system designed to treat hypertension and heart failure via baroreflex activation therapy. Barostim neo had received CE marking for hypertension treatment in Europe and was under clinical evaluation for heart failure in Europe and the US, and for hypertension in the US. CVRx had treated more than 625 patients with its devices at the time. The proceeds were designated for advancing clinical trials and expanding international commercial activities. This marked CVRx's first funding round in several years following a steep economic downturn, after which the company had previously raised $209 million total and employed about 70 people. NEA, with $13 billion in committed capital and investments in over 600 companies, and JJDC, the venture arm of Johnson & Johnson focusing on healthcare, provided strategic support. CVRx continued device innovation, securing multiple US patents in 2013 related to baroreflex activation, electrode designs, and heart failure treatments.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CVRx

When was CVRx founded?CVRx was founded in 2000.
Where is CVRx headquartered?CVRx is headquartered in United States.
How many employees does CVRx have?As of today, CVRx has over 223 employees.
Who is the CEO of CVRx?CVRx's CEO is Kevin Hykes.
Is CVRx publicly listed?Yes, CVRx is a public company listed on Nasdaq.
What is the stock symbol of CVRx?CVRx trades under CVRX ticker.
When did CVRx go public?CVRx went public in 2021.
Who are competitors of CVRx?CVRx main competitors include Owlet, MEZOO, Viromed Medical, EBR Systems, Edap TMS, Apyx Medical, EKF Diagnostics, Sisram Medical, Aroa Biosurgery, Guerbet.
What is the current market cap of CVRx?CVRx's current market cap is $160M.
What is the current revenue of CVRx?CVRx's last 12 months revenue is $60M.
What is the current revenue growth of CVRx?CVRx revenue growth (NTM/LTM) is 16%.
What is the current EV/Revenue multiple of CVRx?Current revenue multiple of CVRx is 2.4x.
Is CVRx profitable?No, CVRx is not profitable.
What is the current EBITDA of CVRx?CVRx has negative EBITDA and is not profitable.
What is CVRx's EBITDA margin?CVRx's last 12 months EBITDA margin is (72%).
What is the current EV/EBITDA multiple of CVRx?Current EBITDA multiple of CVRx is (3.4x).
What is the current FCF of CVRx?CVRx's last 12 months FCF is ($38M).
What is CVRx's FCF margin?CVRx's last 12 months FCF margin is (63%).
What is the current EV/FCF multiple of CVRx?Current FCF multiple of CVRx is (3.9x).
How many companies CVRx has acquired to date?CVRx hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies CVRx has invested to date?CVRx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CVRx

Lists including CVRx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial